Invex Therapeutics Ltd
IXC
Company Profile
Business description
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
Contact
c/- Automic Group
Level 5, 191 St Georges Terrace
PerthWA6000
AUST: +61 1300288664
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
Nvidia remains at the heart of the AI ecosystem.
stocks
Chart of the Week: Software selloff creates opportunity for these two stocks
Can AI disrupt the software business model?
stocks
Market is misinterpreting AI impact on cheap ASX share
Unwarranted sell-off with shares down by half in three months.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,420.10 | 16.00 | -0.17% |
| CAC 40 | 8,559.07 | 39.86 | 0.47% |
| DAX 40 | 25,175.94 | 189.69 | 0.76% |
| Dow JONES (US) | 49,482.15 | 307.65 | 0.63% |
| FTSE 100 | 10,806.41 | 125.82 | 1.18% |
| HKSE | 26,640.14 | 125.58 | -0.47% |
| NASDAQ | 23,152.08 | 288.39 | 1.26% |
| Nikkei 225 | 58,856.98 | 273.86 | 0.47% |
| NZX 50 Index | 13,623.01 | 97.43 | 0.72% |
| S&P 500 | 6,946.13 | 56.06 | 0.81% |
| S&P/ASX 200 | 9,185.30 | 17.60 | -0.19% |
| SSE Composite Index | 4,131.20 | 16.03 | -0.39% |